Glossary
The state-of-the-art glossary for Waldenström’s macroglobulinemia.
Proteasome inhibitors
Proteasome inhibitors in the glossary for Waldenström's macroglobulinemia
Drugs that block the action of proteasomes (cellular complexes that break down proteins)
The ubiquitin proteasome pathway is a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins. Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death. Thus inhibition of the proteosome can shift this equilibrium towards cell death. Three proteasome inhibitors have received regulatory approval and are used routinely in clinical settings, including bortezomib, carfilzomib and ixazomib.1
Glossary overviewReferences
1.Manasanch EE and Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 2017: 14;417–433.
